EyePoint (EYPT) Capital Expenditures Growth (1y) (2011 - 2026)
EyePoint (EYPT) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 143.40% |
| 10 | EyePoint | 1.07 Mn | -221.48 Mn | 168,000.00 | 125.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 125.00% |
| Dec 31, 2025 | 95.95% |
| Sep 30, 2025 | -98.91% |
| Jun 30, 2025 | 105.71% |
| Mar 31, 2025 | -91.78% |
| Jun 30, 2024 | 34.92% |
| Mar 31, 2024 | 10.54% |
| Jun 30, 2023 | -322.02% |
| Mar 31, 2023 | 224.83% |
| Sep 30, 2022 | 814.50% |
| Jun 30, 2022 | 772.00% |
| Sep 30, 2021 | 2.34% |
| Jun 30, 2021 | -3.85% |
| Dec 31, 2020 | 3,100.00% |
| Jun 30, 2020 | 4.00% |
| Mar 31, 2020 | -91.21% |
| Dec 31, 2019 | -95.45% |
| Jun 30, 2019 | -43.18% |
| Mar 31, 2019 | 384.38% |
| Dec 31, 2018 | 248.31% |